A disagreement over how pharma patents in Brazil are examined seems to have come to an end, as Breno Souza, Luisa Rezende and Silvia Costa of Clarke Modet & Co Brazil report.
European developments surrounding the patentability of plants and animals have become rather political, but there are ways for patentees to mitigate the effects of political influence over the patenting process, writes Jane Wainwright of Potter Clarkson.
A new law on supplementary protection certificates will be implemented on April 1, with the application, prosecution and maintenance of SPCs taking centre stage. José Manuel González of Clarke, Modet & Co reports.
President Trump’s decision to pull the US out of the Trans-Pacific Partnership trade deal may have particularly pernicious consequences for the pharmaceutical and biotechnology industries, writes Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff.
As securing patent eligibility for ‘healthcare IT’ applications seems to be becoming easier, companies looking to monetise IP in this area can breathe a sigh of relief. Stacy Taylor of DLA Piper explains more.
Anyone drafting patent licence agreements should follow several tips in order to avoid or better prepare for litigation later on, says Jessamyn Berniker of Williams & Connolly.
Several changes have been made to Italy’s regulatory landscape for biosimilars, as Luca Tosoni of Covington & Burling reports.
IP law has yet to catch up with the technological capabilities of 3D printing, but by taking pre-emptive action, companies can maximise their IP protection under the current legal framework. Arlene Chow and Nitya Anand of Hogan Lovells report.
It appears necessary and perhaps inevitable that further guidance from the UK Court of Appeal will be provided on the issue of second medical use patents, following the high-profile dispute between Warner-Lambert and Actavis. Geoff Hussey and Christopher Burnett of AA Thornton & Co report.
A combination of patents, SPCs and regulatory exclusivities should be considered carefully in order to maximise the exclusivity available for cell therapies, as Glyn Truscott of Elkington + Fife explains.